Pa­tient ex­pe­ri­ence da­ta: Sanofi re­searchers call for more con­sis­ten­cy from FDA

6 days ago
Pharma
Regulatory

Wood­ford fired from flag­ship fund — which won't re­open af­ter all

6 days ago
People
Venture

Sur­pris­ing Wall Street, Rea­ta un­veils pos­i­tive piv­otal da­ta on Friedre­ich’s atax­ia drug

6 days ago
R&D

Boehringer In­gel­heim-backed Aba­los toss­es hat in­to packed on­colyt­ic virus ring

6 days ago
Startups
Venture

[Video] Cel­e­brat­ing tri­al fail­ures, chang­ing the cul­ture and al­ly­ing with Cal­i­for­nia dream­ers: R&D chief Hal Bar­ron talks about a new era at GSK

6 days ago

US mulls tar­iffs on Swiss drug ex­ports, weigh­ing on No­var­tis and Roche –  re­port

Last week
R&D

FDA re­quests ad­di­tion­al time for Flex­ion's sN­DA; Genen­tech re­leas­es da­ta for PhI­II study of Rit­ux­an

Last week
Protocols

Bridge­Bio drops bid to re­claim Ei­dos af­ter di­rec­tors spurn 3 of­fers

Last week
Deals

HR vi­o­la­tion push­es Re­vance co-founder out, vault­ing for­mer Zel­tiq chief to the helm

Last week
People
Pharma

In-house FDA re­view flags a sus­pi­cious im­bal­ance in deaths as Sh­iono­gi hunts an OK for an­tibi­ot­ic

Last week
R&D

A preda­tor's world? Top an­a­lyst sees the 'haves' and the 'haven't­s' di­verge as biotech bub­bles form — and col­lapse

Last week
R&D

Cell ther­a­py start­up rais­es $16 mil­lion to fund its quest for the Holy Grail in re­gen­er­a­tive med­i­cine

Last week
R&D

Eye­ing $86M, Galera leads a pack of three mod­est biotech IPOs push­ing past high pro­file stum­bles

Last week
IPOs

Pelosi drug pric­ing bill promis­es sav­ings, but could gag R&D — CBO analy­sis

Last week
Pharma
R&D

Pfiz­er takes aim at a flag­ship fran­chise at Sanofi and Re­gen­eron — and scores a few di­rect hits

Last week
R&D

First place fin­ish: Eli Lil­ly just moved to fran­chise leader with their sec­ond mi­graine drug OK in 1 year

Last week
Pharma
R&D

ARCH, Soft­Bank-backed Vir Biotech­nol­o­gy un­der­whelms with $143 mil­lion IPO

Last week
IPOs

Court green-lights Clo­vis case af­ter de­tail­ing ev­i­dence the board ‘ig­nored red flags’ on false safe­ty and ef­fi­ca­cy da­ta

Last week
R&D

North­west Bio still hang­ing on; Five Prime's lat­est round of lay­offs claims 70

Last week
Protocols

Zosano Phar­ma CEO pass­es ba­ton down to suc­ces­sor; James Sapirstein takes the helm at Azur­Rx

Last week
Peer Review

Mi­cro­cap Aridis re­cruits Take­da vet Paul Mendel­man to steer late-stage an­ti­body pro­grams in in­fec­tious dis­eases

Last week
People

Long term da­ta echo safe­ty pro­file of Gilead, Gala­pagos' po­ten­tial block­buster JAK in­hibitor

Last week
R&D

Re­searchers find 15% of tri­als could be repli­cat­ed us­ing re­al world da­ta

Last week
Pharma
R&D

Ex-Ab­b­Vie part­ner Prin­cip­ia posts en­cour­ag­ing PhII re­sults for its BTK-in­hibitor

Last week
R&D
First page Previous page 123456 Next page Last page